On Wednesday, Amdocs got a positive adjustment to its Relative Strength (RS) Rating, from 69 to 74.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's unique rating measures price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks tend to have an 80 or higher RS Rating as they begin their largest runs. See if Amdocs can continue to rebound and hit that benchmark.
Amdocs is working on a cup with handle with a 93.34 buy point. See if the stock can clear the breakout price in heavy trading.
The company showed 6% earnings growth last quarter, while sales growth came in at -11%. Look for the next report on or around May 7.
The company holds the No. 11 rank among its peers in the Computer-Technical Services industry group. Dave, IBEX and Innodata are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
